Search company, investor...
AVEO Oncology company logo

AVEO Oncology

Founded Year



Acq - P2P | Acquired

Total Raised




About AVEO Oncology

AVEO Oncology (Nasdaq: AVEO) focuses on biopharmaceuticals offering medicines for patients with cancer. It markets FOTIVDA (tivozanib) in the United States. AVEO Oncology was formerly known as AVEO Pharmaceuticals. The company was founded in 2001 and is based in Boston, Massachusetts. In January 2023, AVEO Oncology was acquired by LG Chem.

Headquarters Location

30 Winter Street

Boston, Massachusetts, 02108,

United States


Missing: AVEO Oncology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AVEO Oncology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AVEO Oncology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AVEO Oncology is included in 2 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest AVEO Oncology News

LG Chem Completes Acquisition of AVEO Oncology

Jan 20, 2023

LG Chem Completes Acquisition of AVEO Oncology Share LG Chem Completes Acquisition of AVEO Oncology By Choi Moon-hee × LG Chem CEO Shin Hak-cheol (fourth from left in the front row) and Michael Bailey (fourth from right on the front row), president and CEO of AVEO, pose for a photo with other officials from the two companies. LG Chem has completed its acquisition of AVEO Oncology, a U.S. biopharmaceutical company focused on oncology, in an all-cash transaction with an implied equity value of US$571M on a fully diluted basis, the company announced on Jan. 19. “We are excited to complete LG Chem’s acquisition of AVEO, which will position us to deliver on our mission of becoming one of the world’s leading oncology companies with a robust clinical pipeline of innovative therapies,” said Shin Hak-cheol, CEO of LG Chem. AVEO plans to accelerate the commercialization of new anti-cancer drugs developed by LG Chem Life Sciences. With strong capabilities in early-stage R&D and production process, LG Chem Life Sciences will be positioned to pursue promising anti-cancer therapies and commercial processes for pre-clinical and early clinical trials, while AVEO, with its broad expertise in clinical development and sales in the U.S. market, will oversee clinical development and commercialization. “The merger extends LG Chem Life Sciences’ commercial footprint to the U.S., diversifies our pipeline and advances our combined capabilities with AVEO, accelerating our ability to develop, commercialize and acquire world-class cancer therapies,” said Son Jee-woong, president of LG Chem Life Sciences. “We look forward to working closely with AVEO’s experienced and talented team as we welcome them to the LG Chem family.” “This transaction delivered significant value to our shareholders and AVEO is now positioned to benefit from the support and resources of LG Chem as we advance our mission of improving the lives of patients with cancer,” said Michael Bailey, president and CEO of AVEO. “We look forward to our next chapter of growth as we realize the tremendous potential of our promising pipeline and leverage our combined capabilities to deliver continued progress across our clinical and pre-clinical stage anti-cancer therapies.” AVEO will continue to be led by president and CEO Michael Bailey, chief commercial officer Mike Ferraresso, chief operating officer Jeb Ledell and senior vice president, general counsel Danielle Holland. AVEO is also welcoming Martin Birkhofer as its chief medical officer and will have Erick Lucera serve as its chief financial officer during a temporary transition period. A new CFO is expected to be appointed by LG Chem. While AVEO is now a wholly owned subsidiary of LG Chem Life Sciences Innovation Center, Inc., AVEO will continue to operate under the AVEO Oncology name. The combined company will fully maintain operations in Boston and Cambridge, Massachusetts, where both AVEO and LG Chem Life Sciences Innovation Center are based. POPULAR

AVEO Oncology Frequently Asked Questions (FAQ)

  • When was AVEO Oncology founded?

    AVEO Oncology was founded in 2001.

  • Where is AVEO Oncology's headquarters?

    AVEO Oncology's headquarters is located at 30 Winter Street, Boston.

  • What is AVEO Oncology's latest funding round?

    AVEO Oncology's latest funding round is Acq - P2P.

  • How much did AVEO Oncology raise?

    AVEO Oncology raised a total of $131.2M.

  • Who are the investors of AVEO Oncology?

    Investors of AVEO Oncology include LG Chem, OSI Pharmaceuticals, MPM Capital, Prospect Venture Partners, Greylock Partners and 18 more.

  • Who are AVEO Oncology's competitors?

    Competitors of AVEO Oncology include Esperance Pharmaceuticals, Acetylon Pharmaceuticals, Angstrom Pharmaceuticals, Onconova Therapeutics, Nanobiotix and 12 more.

Compare AVEO Oncology to Competitors


Neuromark is aiming to develop genetic answers for the new era in neuropsychiatry.

Marillion Pharmaceuticals

Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..

NAICONS (New Anti Infective CONSortium)

NAICONS (New Anti-Infective CONSortium) is a new organization aiming at integrating resources in the field of infectious diseases to create a strategic and operative hub dedicated to discover and develop antibiotics targeting unmet medical needs.

Psimei Pharmaceutical

Psimei Pharmaceuticals is developing boron-based drugs for applications in Photon Activation Therapy (PAT). This involves the use of standard radiotherapy to activate boron-based compounds which selectively target solid tumours. This results in an amplification of the therapeutic effect of conventional radiotherapy. Pre-clinical data for Psimei's lead product, PP200PAT, has demonstrated 90% true cure rates at 6 months in tumour models compared with 30% for conventional radiotherapy alone. It also enabled much shorter treatment regimes - days as opposed to weeks. This drug is being prepared for clinical development.

ISA Pharmaceuticals

ISA Pharmaceuticals develops treatments for various cancers and infectious diseases. It focuses on the development of synthetic peptide vaccines that boost the immune system to recognize specific peptides associated with specific types of cancer and subsequently destroy the tumor cells. The company was founded in 2004 and is based in Oestgeest, Netherlands.


Deliverance of therapeutic drugs directly to the site without risk to healthy tissue.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.